Company overview. Watson Pharmaceuticals, Inc. (NYSE ticker: WPI) was a U.S. generic and specialty pharmaceutical company founded in 1984 and headquartered in Parsippany, New Jersey (originally Corona, California). It was publicly traded on the NYSE. Around 2011–12 it employed roughly 7,700 people and reported annual sales in the ~$4.5 billion range; after its 2012 acquisition of Switzerland-based Actavis Group, the combined company reported pro forma 2012 revenues above $8 billion with about 17,000 employees. In 2012 Watson adopted the Actavis name; via later mergers (Warner Chilcott, then Actavis plc's inversion to Ireland) it became part of Allergan plc, and ultimately the generics business was acquired by Teva. Watson as a distinct corporate name no longer exists.
Products / operations. Watson developed, manufactured and marketed generic and branded pharmaceuticals and active pharmaceutical ingredients. Its segments included Global Generics (marketing roughly 190 prescription product families in the U.S., with cardiovascular, pain, CNS, diabetes and dermatology products), Global Brands/Specialty Brands (urology and women's health), Anda, Inc., a U.S. generic drug distributor, and Medis, an international generics out-licensing business. It also pursued biosimilars. It was an operating company, not a patent-assertion entity.
Patent-litigation posture. Watson appears in the tracked data twice, both times as a defendant and zero times as plaintiff — the profile of an operating company being sued over its products, not an NPE. Both cases are Hatch-Waxman ANDA suits brought by brand manufacturer Celgene in the District of New Jersey (D.N.J.), a common venue for pharmaceutical patent disputes.
Notable cases. Both tracked matters are Celgene Corporation v. Natco Pharma Ltd. et al. (D.N.J., filed Oct. 2010 and July 2012). Celgene alleged that a generic lenalidomide (Revlimid) ANDA filed by Natco, partnered with Malta-based Arrow International and Watson Laboratories, infringed Celgene's patents. Watson/Arrow acted as Natco's U.S. commercialization partner. The dispute was resolved by a December 2015 settlement and 2016 consent judgment permitting volume-limited generic entry beginning 2022. The settlement later featured in follow-on antitrust litigation against Celgene/Bristol-Myers Squibb.